Scientific advances in obesity treatment have brought about GLP-1 medications, offering significant weight-loss and cardiometabolic improvements. However, the high cost and low long-term adherence rates raise concerns about achieving a meaningful return on investment for employers and health plans. To address this, organizations should look for comprehensive solutions that include personalized treatment options, support for patients on GLP-1 medications, and streamlined processes to ensure access to care. As the global market for GLP-1 therapies continues to grow, organizations must proactively manage costs and patient adherence to maximize the benefits of these treatments and ensure sustainable progress in obesity and diabetes care.
Source link
The Promise and Challenge of GLP-1 Medications: Ensuring ROI in Obesity Care
